CA2339992C - Orally disintegrable tablet forming a viscous slurry - Google Patents
Orally disintegrable tablet forming a viscous slurry Download PDFInfo
- Publication number
- CA2339992C CA2339992C CA002339992A CA2339992A CA2339992C CA 2339992 C CA2339992 C CA 2339992C CA 002339992 A CA002339992 A CA 002339992A CA 2339992 A CA2339992 A CA 2339992A CA 2339992 C CA2339992 C CA 2339992C
- Authority
- CA
- Canada
- Prior art keywords
- dosage form
- weight
- amount
- mouth
- weight based
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Abstract
A dosage form which rapidly disintegrates in the mouth and forms a viscous slurry of either microcapsules or a powder is described. The rapidly disintegrating dosage form is meant for direct oral administration by placin g a tablet or capsule in the mouth of a patient. Upon disintegration, a viscosity of the resulting slurry increases so as to form an organoleptically pleasant viscous material which retards the spread of insoluble materials including the drug.
Description
ORALLY DISINTEGRAF,LE TABLET FORMING A VISCOUS SLURRY
TECHNICAL FIELD
The invention relates to the fields of pharmacy and medicine and to orally disintegrable dosage forms for the delivery of sustained or extended release microcapsules and/or prompt release coated or non-coated drug particles.
BACKGROUND ART
There are many formulations known for administering extended or sustained release forms of various medicines. A
common method involves the administration of microencapsulated or otherwise coated drug substances. Coating can be errodable or disintegrable or it can be selectively porous, effectively controlling the release or diffusion of the drug contained within it. The administration of such particles is, not without complexity. Tableting may crush the particles interfering with their otherwise preplanned drug administration rate. Suspension or liquid vehicles may be desirable, but the potential fOr le8kGcje o~ the drug .io laoroze~d. L'apSUl2S
containing granules or beads may be an alternative. However, each new coating stage adds additional complexity and can modify the overall release profile of the drug.
Indeed, this latter problem is common to tablets as well. While much care ma~~ be taken in ensuring that the microencapsulated drug wi-~ release at a certain rate, placing sufficient material into a hard tablet for ingestion can change the release profile. I~ will take some time for the body to sufficiently digest the tablet and allow it to decompose or disintegrate intc its component parts thereby releasing the microcapsules or microparticles. This adds an additional variable to the release profile and complicates formulation s~.gnificantly.
One method of addressing these complications is by the provision of in-mouth, rapidly disintegrable tablets.
These tablets will disintegrate in the mouth and release the microcapsules or microparticles which can then be swallowed.
In essence, the tablet is useful for conveying the microencapsulated materials to the body. However, it disintegrates sufficiently rapidly such that it will not become S an impediment or a significant factor in the overall release profile. By the use of this technology, ideally the release rate and profile of the drug would be identical to that of a standard tablet which is ingested or to that of an equivalent amount of microparticles which are swallowed.
Nonetheless, there is considerable room for improvement. Sustained-release or extended-release microcapsules and microparticles tend to be relatively larger and are often relatively hard. If an in-mouth delivery system is used, these particles are then released into the mouth and produce a sandy or gritty feel. This feel is exacerbated by large quantities of microencapsulated materials and/or the inclusion of relatively larger, tactily more significant, particles. It is an aim of the invention to address this problem.
Other problems are encountered in the formulation of prompt release, orally disintegrable tablets, especially those containing taste masked drug substances. These problems include "local accumulation." Upon disintegration in the mouth, local accumulations of powder may occur which are not immediately swallowed. Powder may adhere to various parts of the oral cavity such as the tongue, mucus membranes and between the teeth. These local accumulations of powder may have an unpleasant mouth fee. Moreover, if the dosage form contains unpleasant tasting drug particles which are taste masked by means of coating, adherence in the oral cavity allows a greater opportunity for dissolution of the coating and, hence, release of the drug into the oral cavity. The dissolved drug diffuses through the saliva to reach the taste buds, resulting in the patient experiencing an unpleasant taste.
TECHNICAL FIELD
The invention relates to the fields of pharmacy and medicine and to orally disintegrable dosage forms for the delivery of sustained or extended release microcapsules and/or prompt release coated or non-coated drug particles.
BACKGROUND ART
There are many formulations known for administering extended or sustained release forms of various medicines. A
common method involves the administration of microencapsulated or otherwise coated drug substances. Coating can be errodable or disintegrable or it can be selectively porous, effectively controlling the release or diffusion of the drug contained within it. The administration of such particles is, not without complexity. Tableting may crush the particles interfering with their otherwise preplanned drug administration rate. Suspension or liquid vehicles may be desirable, but the potential fOr le8kGcje o~ the drug .io laoroze~d. L'apSUl2S
containing granules or beads may be an alternative. However, each new coating stage adds additional complexity and can modify the overall release profile of the drug.
Indeed, this latter problem is common to tablets as well. While much care ma~~ be taken in ensuring that the microencapsulated drug wi-~ release at a certain rate, placing sufficient material into a hard tablet for ingestion can change the release profile. I~ will take some time for the body to sufficiently digest the tablet and allow it to decompose or disintegrate intc its component parts thereby releasing the microcapsules or microparticles. This adds an additional variable to the release profile and complicates formulation s~.gnificantly.
One method of addressing these complications is by the provision of in-mouth, rapidly disintegrable tablets.
These tablets will disintegrate in the mouth and release the microcapsules or microparticles which can then be swallowed.
In essence, the tablet is useful for conveying the microencapsulated materials to the body. However, it disintegrates sufficiently rapidly such that it will not become S an impediment or a significant factor in the overall release profile. By the use of this technology, ideally the release rate and profile of the drug would be identical to that of a standard tablet which is ingested or to that of an equivalent amount of microparticles which are swallowed.
Nonetheless, there is considerable room for improvement. Sustained-release or extended-release microcapsules and microparticles tend to be relatively larger and are often relatively hard. If an in-mouth delivery system is used, these particles are then released into the mouth and produce a sandy or gritty feel. This feel is exacerbated by large quantities of microencapsulated materials and/or the inclusion of relatively larger, tactily more significant, particles. It is an aim of the invention to address this problem.
Other problems are encountered in the formulation of prompt release, orally disintegrable tablets, especially those containing taste masked drug substances. These problems include "local accumulation." Upon disintegration in the mouth, local accumulations of powder may occur which are not immediately swallowed. Powder may adhere to various parts of the oral cavity such as the tongue, mucus membranes and between the teeth. These local accumulations of powder may have an unpleasant mouth fee. Moreover, if the dosage form contains unpleasant tasting drug particles which are taste masked by means of coating, adherence in the oral cavity allows a greater opportunity for dissolution of the coating and, hence, release of the drug into the oral cavity. The dissolved drug diffuses through the saliva to reach the taste buds, resulting in the patient experiencing an unpleasant taste.
SUMMARY OF THE INVENTION
The present invention solves these problems by, in one aspect, providing an orally disintegrable tablet suitable for use in the delivery of sustained or extended release S formulations of coated granules, coated particles or microcapsules.
Applicants have found that a method of addressing the distasteful sensation which may accompany the use of extended or sustained release coated formulations is by providing a l0 material which will decompose or disintegrate in the mouth so as to form a relatively viscous slurry with saliva. This viscous saliva slurry will help contain the particles as a loose but cohesive mass thereby preventing the particle from distributing throughout the mouth, i.e., under the tongue, 15 between the gums and lips, etc. This therefore provides a greatly enhanced organoleptic sensation. This is accomplished by providing an in-mouth disintegrable formulation (orally disintegrating tablets, capsules, etc.) that includes an in-mouth viscosity enhancer which provides a pleasant mouth feel 20 and helps to cause the individual particles to associate with each other and with saliva to thereby incorporate the extended release particles into a salivary mass of increased viscosity.
This in turn allows the particles to stay together and glide smoothly and be easil~, swallowed. This in-mouth viscosity 25 enhancing material can be, for example, an in situ formed gel or a material such as gums or various polymers. Mixtures are also contemplated.
The tablet preferably contains between about 10 and about eo% of an extended release coated material by weight of 30 the tablet. For convenience, we will refer herein to these coated materials as "microcapsules." However, it should be urld.erstood that this term contemplates t~.~ --,.e of any extended, enteric or sustained-release vehicle, including microgranulC~, granules, microcapsules, particles, microparticles, adsorbates 35 and the like known ;in the industry. Indeed, these particulate WO OOI09090 PC'T/US99/18400 materials, referred to collectively herein as "microcapsules,"
need not necessarily be coated at all; so long as they can achieve an extended release. These microcapsules generally have a particle size ranging from between about 50 to about 3,000 microns and include between about 5 and about 70% of a coating based on the weight of the microcapsules. The coating is an extended or enteric release coating.
The tablet also generally includes between about 5 and about 60% of a rapidly dissolvable sugar or sugar alcohol l0 filler. The rapidly dissolvable sugar or sugar alcohol filler has a particle size selected to be complementary to the particle size of the microcapsules and generally ranges between about 300 and about 1,500 microns. The tablet also includes between about 0 and about 35% of a binder, including insoluble filler-binders, between about 1 and about 40% of a disintegrant; and between about 0 and about 50% of an effervescent couple. The sugar or sugar alcohol, binder disintegrant and if present, the effervescent couple are all provided in amounts based on the weight of the finished tablet.
By the use of the present invention one can develop in-mouth dis.integrable tablets which can disintegrate in the mouth in under a minute, preferably under 30 seconds. The thus disintegrated tablet releases the sustained or extended release microcapsules into the mouth. The use of .the viscosity enhancer helps to maintain the available saliva, excipients and microparticles as an integral mass. However, the resulting slurry remains both easy and pleasurable to swallow.
The present invention therefore solves the problems facing the prior art. Even with relatively large microcapsules, it is possible to obtain a dosage form which can disintegrate rapidly in the mouth and yet results in a pleasant crganoleptic mouth feel. Relatively large microcapsules can be released into the mouth without a significant amount of chewing which could break the microcapsules~ and/or alter their release 3J profile. The microcapsules are bound together, in a loose WO 00/09090 PCTlUS99/18400 confederation, which reduces this tendency to dissipate throughout the mouth oz the patient causing irritation, discomfort, and an adverse organoleptic sensation. Ideally, the pharmoco-kinetic performance of the drug administered 5 through this dosage form will not be in any way altered by a comparison of the direct administration of equal amounts of non-tableted extended release microcapsules. Again, these increased organoleptic properties, coupled with the convenience of rapid and in-mouth disintegration, greatly assists in l0 assuring compliance.
In another aspect of the present invention, closely related to that just described, the present invention provides a slurry generated in the mouth of a patient following the placement of a dosage form in the patient's mouth to serve as a binding medium to hold certain non-extended release/non-enteric coated active ingredients together as a mass which can easily be swallowed. This decreases the opportunity for the particles or powders to stick to membranes or between teeth, leaving an unpleasant mouth feel and/or unpleasant taste. Moreover, to the extent that any coated or encapsulated drug was to permeate the coating, it would encounter a viscous salivary mixture through which the dissolved drug must diffuse in order to reach the taste buds Since diffusion through the viscous medium is slow, little, if any, of the drug is tasted before it is swallowed. These various mecha:,isms improve the organoleptic properties of the medication. Of course, the use of both the extended release mic~ocaps~.:ies and powders in a single dosage form are also contemplated. This would provide both an immediate release of drug and prolonged release as well.
It will be appreciated that the term "powder" as used herein contemplates both a true powder, as well as truly crystalline materials, microgranulated and granulated materials, agglomerates, adsorbates and the like. In addition, when these powders are coated, the coating contemplated is a ~5 rapid release coating -- one which can assist in providing WO 00/09090 PC'T/US99/18400 effective taste masking while providing minimal inference with the coated active ingredient's normal dissolution profile.
Ideally these coatings will dissolve, disintegrate or become sufficiently porous to allow the full release and dissolution of the coated drug in a manner consistent with the administration of the same drug in a completely uncoated fashion. Certainly, the use of these "coated powders" should not alter the dissolution rates of the drug in the digestive tract by more than an hour and preferably by less than half an hour.
In this way, these powder materials are distinguished from "microcapsules" having extended, sustained, or enteric coatings as discussed herein. For convenience, these coated and uncoated species will be encompassed within the term "powder."
Furthermore, while the various aspects of the present invention will principally be described in terms of the use of microcapsules i.e., extended,' enteric or sustained release species, the formulations described are applicable to both 2o microcaDSUles and powders a~less noted otherwise. Therefore, for example, in a particular formulation, an equivalent amount of a powder can be substituted for an equivalent amount of microcapsules. Of course, some adjustments may be necessary to account for the relative di~ferences in the weight of the coatings used. However, the amount of uncoated drug should be eauivalent in each case.
Another aspect o~ the present invention is the discovery of an interesting synergy which exists by the use of effervescent materials in combination with the dosage forms described herein. In addition to the normal role of effervescence in stimulating the mouth's production of saliva, speeding disintegration, the aiding in taste masking, the presence of effervescence in the dosage forms of the present invention actuall,~~ enhances the overall performance of these dosage forms. it is believed that effervescence helps provide w0 00/09090 PCTlUS99/18a00 a driving force and a mixing action which increases the speed with which the viscosity of the resulting slurry is formed.
The effervescence also is believed to help carry the slurry away from the dissolving and disintegrating surface of the tablet such that the viscous slurry does not completely encapsulate same and retard further disintegration. Not a great deal of effervescence is required to obtain these results although the organoleptic properties of the dosage forms can be significantly altered based on the amount of effervescent material present.
BEST MODE OF CARRYING OUT INVENTION
In accordance with the present invention, "orally disintegrable" mear_s that the tablet will disintegrate substantially into its component parts (e. g. the powder, microcapsules and insoluble excipients, etc.) within three minutes, preferably within two minutes or less and more preferably within about one minute or less. For very large tablets, i.e., ?,500 mg or above, greater than three may be required. However, such extended disintegration time is contemplated in the phrase "substantially disintegrated."
"Dissolvable" or "dissolution," in accordance with the present invention, refers to certai:. components of the tablet of the present invention which are substantially soluble in water and saliva. At least about 500 by weight of such ingredients will dissolve and preferably within about 90 seconds of a tablet being placed in a patient's mouth.
Microcapsules in accordance with the present invention, includes active ingredients which are in the form of coated particles, microparticles, microcapsules, granules, microgranules, adsorbates, etc. and ar_e provided in an amount of between about l0 and about 80% based on the tablet's weight.
This means that between to and 80% of the weight of the finished tablet is made up of microcapsules. More preferably, the amount of microcapsules ranges from between about 20-70's by weight.
- W O 00/09090 PCTN S99/ I S.t00 These microcapsules should have a particle size ranging from between about 50 to about 3,000 microns, and more preferably between about 300 to about 2,000 microns.
Of these microcapsules, between about 5 to about 70%
by weight of the microcapsules themselves is made up of the enteric, sustained release or extended release coating.
Preferably, the amount of coating, by weight of the microcapsules, ranges from between about 10 to about 40% and more preferably from between about l0 to about 200.
The coating in accordance with the present invention is an extended or enteric release coating. By extended or enteric release it is understood that while the microcapsules are rapidly dispersed in the mouth the active ingredients or drug itself is released from the microcapsules slowly or in a manner that alters its otherwise normal release profile. By the use of these coatings, the time necessary between doses of drug can be extended relative to the use of the same quantity of uncoated particles or microcapsules. Preferably the extended release coatings in accordance with the present invention will provide for a release of drug, with as uniform a rate as possible, over a period of time ranging from between about 4 to about 48 hours and more preferably from between about 4 to about 24 hours.
Preferred extended release coatings in accordance with the present invention include, for example, cellulose ethers, cellulose esters, polymethacrylates and copolymers, polvvinylacetate copolymers. Cellulose ethers include hydroxy propylmethyl cellulose, ethyl cellulose, hydroxypropyl cellulose and sodium carboxymethyl cellulose. Cellulose esters include hydroxypropylmethyl cellulose phthalate, cellulose-acetate phthalate, and hydroxypropylmethyl cellulose acetate succinate. Polymethacrylates include methacrylic acid/methyl methacrylate copolymers, methacrylic acid-methyl acrylate copolymers and dimethyl amino-methyl methacrylate copolymers.
Pclyvin~~l acetate copolymers include vinylacetate/vinylpyrrolidone copolymers polyvinylacetate phthalate and polyvinylpyrrolidone. Enteric coatings include, without limitation, cellulose acetate phthalate, shellac, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, and a family of polymers sold under the trademark EUDRAGIT~' .
The active ingredient can include pharmaceutical ingredients, vitamins, minerals and dietary supplements.
Pharmaceutical ingredients may include, without limitation, l0 antacids, analgesics, anti-inflammatories, antipyretics antibiotics, antimicrobials, laxatives, anorexics, antihistamines, antiasthmatics, antidiuretics, anti-flatuents, antimigraine agents, biologicals (proteins, peptides, oligonueleotides, etc.) anti-spasmodics, sedatives, antihyperactives, antihypertensives, tranquilizers, decongestants, beta blockers and combinations thereof. Also encompassed by the terms "active ingredient(s),"
"pharmaceutical ingredientls)" and "active agents" are the drugs and pharmaceuticall.~~ active ingredients described in Mantelle, U.S. Patent No. 5,23,957, in columns 18 through 21.
As used in this disclosure, the term "vitamin" refers to trace organic substances that are required in the diet. For the purposes of the present invention, the term "vitamin(s)"
includes, without limitation, thiamin, riboflavin, nicotinic acid, pantothenic acid, pyridoxine, biotin, folic acid, vitamin H12, lipoic acid, ascorbic acid, vitamin A, vitamin D, vitamin E and vitamir. K. Also included within the term "vitamin" are the coenzymes thereof. Coenzymes are specific chemical forms of vitamins. Coenzymes include thiamine pyrophosphates (TPF), flavin mononucleotide (FMM), flavin adenine dinucleotide (FAD), Nicotinamide adenine dinucleotide (NAD), Nicotinamide adenine dinucleotide phosphate (NADP), Coenzyme A (CoA), pyridoxal phosphate, biocytin, tetrahydrofolic acid, coenzyme lipoyllysine, II-cis-retinal, and WO 00/09090 PC'TNS99/18400 1,25-dihydroxycholecalciferol. The term "vitamin(s)" also includes choline, carnitine, and alpha, beta, and gamma carotenes.
The term "mineral" refers to inorganic substances, 5 metals, and the like required in the human diet. Thus, the term "mineral" as used herein includes, without limitation, calcium, (calcium carbonate), iron, zinc, selenium, copper, iodine, magnesium, phosphorus, chromium and the like, and mixtures thereof. The term "dietary supplement" as used herein 10 means a substance which has an appreciable nutritional effect when administered in small amounts. Dietary supplements include, without limitation, such ingredients as bee pollen, bran, wheat germ, kelp, cod liver oil, ginseng, and fish oils, amino-acids, proteins and mixtures thereof. As will be appreciated, dietary supplements may incorporate vitamins and minerals.
In general, the amount of active ingredient incorporated in each tablet or dosage form may be selected according to known principles of pharmacy. An effective amount ?0 of pharmaceutical ingredient is specifically contemplated. By the term "effective amount," it is understood that, with respect, to for example, pharmaceuticals, a "pharmaceutically effective amount" is contemplated. A "pharmaceutically effective amount" is the amount or quantity'of a drug or pharmaceutically active substance which is sufficient to elicit the reauired or desired therapeutic response, or in other words, the amount which is suf~icient to elicit an appreciable biological response when administered to a patient. As used with reference to a vitamin or mineral, the term "effective amount" means an amount at least about 10% of the United States Recommended Daily Allowance ("RDA") of that particular ngredient for a patient. For example, if an intended ingredient is vitamin C, then an effective amount of vitamin C
would include an amount of vitamin C sufficient to provide l0%
or more of the RDA. Typically, where the tablet includes a mineral or vitamin, it will incorporate higher amounts, preferably about 100% or more of the applicable RDA.
The amount of active ingredient used can vary greatly. Of course, the size of the dosage form, the requirements of other ingredients, and the number of, for example, tablets which constitute a single dose will all impact the upper limit on the amount of pharmacologically active ingredient which can be used. However, generally, the active ingredient is provided in an amount of between greater than zero and about 80% by weight of the finished tablet and, more preferably, in a range of between greater than zero and about 60's by weight thereof. Put in other terms, the active ingredient can be included in an amount of between about 1 microgram to about 2 grams, and more preferably between about 0.01 and about 1000 milligrams per dosage form, i.e., per tablet.
Dosage forms in accordance with the present invention also includes between about S and about 600 of a rapidly dissolvable sugar or sugar alcohol filler. This amount is 2o based on the weight of the finished tablet. More preferably, the amount of such =filler will range from between about 10 to about 35% by weight based on the tablet.
Rapidly dissolvable sugar and sugar alcohol in accordance with the present invention include, for example, mannitol, lactose, sucrose, maltose, dextrose, sorbitol, xvlitol, maltitoi, iactito'~, and maltadextrins. Mannitol and other similar compou:~ds ha~,-~.na a negative heat of solution are preferred because they provide a particularly pleasant sensation enhancing the organoleptic experience of taking the tablet of the present invention. Most preferably, the filler is sucrose, mannitol, xylitol, lactose and maltose. When used at all, preferably only rapidly water soluble filler materials should be used.
WherF necessary, granulated materials are used such that the particle size of the filler is complementary to that WO 00/09090 ' pCT/US99I1840t1 of the particle size of the microcapsules. "Complementary"
does not mean that the particle sizes need be exactly the same.
However, the greater the degree of similarity, the greater the homogeneity of the material. The greater homogeneity, in turn, results in much greater uniformity of disintegration and dissolution. The particle size of the filler should therefore range from between about i00 to about 2,800 and more preferably between about 150 to about 1,540 microns.
For tableting purposes, a binder is preferred. The l0 binder should be present in an amount of between about o to about 35's by weight based on the weight of the tablet.
Preferably, the binder will be present in an amount which is greater than zero and indeed, in an amount of between about 3 to about 15x. Water soluble binders are preferred. But generally, such binders are water insoluble. Therefore, the effort should be made to minimize the content of such binders as the higher the overall content of insoluble materials such as the coated active, the lower the overall organoleptic quality of the formulation. Certain binders such as a number of insoluble filler-binders including microcrystalline cellulose sold under the trade name "AVICELT""" have additional advantageous properties that, despite their insolubility, make them nonetheless more desirable than other similar binders. A
number of AVICELT" formulations such as, for example, type PH113 available from FMC Corpora~ion, Princeton, New Jersey can act as a dry binder. However, when placed in an aqueous environment such as, ir. a patient's mouth, the binder can actually aid in the disintegration of the tablet. In addition, microcrystalline cellulose imparts an almost creamy mouth feel 3o which helps offset the negative impact of its insolubility.
The use of such binders therefore helps reduce the overall amount of disintegrant which needs be used. Other binders include alginic acid, sodium alginate, starch, modified starches and other water swellable binders. Methyl cellulose is also preferred. Note that certain binders can also be used and classified as disintegrants as is knawn in the industry.
Other disintegrants are also often desirable.
Disintegrants, such as crospovidone (cross-linked polyvinyl pyrrolidone (cross-linked "PVP")) are generally water insoluble. While they add to the rapid disintegration of the formulation, their inclusion can also add to the total content of insoluble ingredients making it more difficult to strike a balance between disintegration/dissolution speed and the resulting organoleptic sensation. Preferably, the amount of disintegrant will range from between greater than zero, i.e., about 1 to about 40% by weight based on the weight of the tablet and more preferably between about 3 to about 20%. Other disintegrants useful include sodium starch glycolate, croscarmallose sodium, microcrystalline cellulose and starch.
An effervescent couple is also preferred for use in accordance with the present invention. When present at all, it can be provided in a relatively small amount. The effervescent couple provides a number of advantages in the overall context of the present formulation. First, it aids in the disintegration of the tablet making it easier for the dissolvable constituents to dissolve and rapidly create a slurry. The presence of effervescence can also help stimulate the generation o~ saliva again facilitating disintegration, dissolution and the formation of an in-mouth slurry. Finally, many find the sensation o~ a mild amount of effervescence to be pleasing and this helps fac,~~itate compliance by enhancing the organoleptic properties of the tablet.
The term effervescent couples) includes compounds which evolve gas. The preferred effervescent couples evolve gas by means of chemical reactions which take place upon exposure of the effervescent couple to water and/or to saliva in the mouth. The bubble or gas generating reaction is most often the result of the reaction of a soluble acid source and alkali metal carbonate or carbonate source. The reaction of these two general classes of compounds produces carbon dioxide gas upon contact with water included in saliva.
Such water activated materials should be kept in a generally anhydrous state with little or no absorbed moisture or in a stable hydrated form since exposure to water will prematurely disintegrate the tablet. The acid sources or acid may generally include food acids, acid anhydrides and acid salts. Food acids include citric acid, tartaric acid, malic acid, fumaric acid, adipic acid and succinic acids, etc.
to Because these acids are directly ingested, their overall solubility in water is less important than it would be if the effervescent tablet formulations of the present invention were intended to be dissolved in a glass of water. Acids, anhydrides and salts may be used. Salts may include sodium, dihydrogen phosphate, disodium dihydrogen pyrophosphate, acid citrate salts and sodium acid sulfite.
Carbonate sources include dry solid carbonate and bicarbonate salts such as sodium bicarbonate, sodium carbonate, potassium bicarbonate and potassium carbonate, magnesium 2o carbonate and sodium sesquicarbonate, sodium glycine carbonate, L-lysine carbonate, arginine carbonate and amorphous calcium carbonate.
The effervescent couple of the present invention is not always based upon a reaction which forms carbon dioxide.
Reactants which evolve oxygen or other gases which are safe are also considered within the scope. Where the effervescent couple includes two mutually reactive components, such as an acid source and a carbonate source, it is preferred that both components react completely. Therefore, an equivalent ratio of components which provides for equal equivalents is preferred.
For example, if the acid used is diprotic, then either twice tire amount of a mono-reactive carbonate base, or an equal amount of a di-reactive base should be used for complete neutralization to be realized. However, in other embodiments of the present invention, the amount of either acid or WO 00/09090 PCT/US99/18.100 carbonate source may exceed the amount of the other component.
This may be useful to enhance taste and/or performance of a tablet containing an overage of either component. In this case, it is acceptable that the additional amount of either 5 component may remain unreacted. It may be desirable to add an excess of one component in order that the excess may react with an in situ gel forming substance. An example of this is an excess of sodium bicarbonate to react with alginic acid to form a gel.
l0 In general, the effervescent couple may be provided in an amount of between greater than zero to about 50% by weight of the tablet. More preferably, it will be provided in an amount of greater than zero to about 350. It is preferred, however, that the effervescent Couple be provided in an amount 15 which is greater than zero. Indeed, while neither a binder nor an effervescent couple is required to provide acceptable performance, the use of at least one of a binder and/or effervescent couple is preferred. Most preferably, some amount of both are provided. An effervescent couple may not be needed when certain in-mouth viscosity enhancers are used. In other instances, the liberated gas in conjunction with the viscosity enhance. results in a slurry of the required viscosity.
The in-mouth viscosity enhancer or viscosity modifiers in accordance witr: the present invention can include gels, in-situ gel formers, gums and polymeric materials. The in-mouth viscosit~~ enhancing material may include, for example, in-situ gel Dormers such as alginic acid and a complimentary soluble metal carbonate, a gum such as arabic, xanthan, guar, etc. and carbopolvmers such as carbopols available from Croda, Inc., hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, etc. Most preferred are ~;ethv lce'.lules~ , i-v:~;:roy~propylmethyl cellulose , hydroxyethyl cellulose, carbolpol and silicon dioxide. These materials are provided in an amount which is sufficient to increase the viscosity oI the slurry that results from the disintegration WO 00/09090 PC'T/US99/18400 and dissolution of the various other components of the tablet in a patient's mouth. However, the amount of such in-mouth viscosity enhancing ingredients must be controlled to ensure that an organoleptically acceptable slurry results and that the increased viscosity does not too adversely affect either the in-mouth disintegration time or the organoleptic properties of the formulation.
The amount of these viscosity enhancers used to provide sufficient cohesion and form an organoleptically l0 acceptable (i.e. one which is palatable and preferably pleasant) slurry will vary greatly depending upon a number of factors including the volume of medicine to be delivered, the type of patient (the viscosity may need to be different for children than for adults) the disintegration time and the specific type of viscosity enhancer used. The amount used will be that which provides an effective amount of viscosity to the slurry resulting from the disintegration of the dosage form, the dissolution of the saliva dissolvable species and the release of the insoluble species. Generally, the amount of viscosity enhancer will range from between about 1 and about 36~ by weight and more preferably between about 2 and about 200. In any event, sufficient viscosity enhancers should be used to provide effective viscosity enhancement. This means that the resulting viscosit;,- of the slurry should range from between 25,000 to 500,000 (centipoise) CPS and more preferably between about 25,000 and about 300,000 CPS.
A lesser amount of a gum, for example, may be necessary than the amount of components necessary for the in-situ formation of a gel. It may also be necessary to include the varying proportions of viscosity modifiers. Thus, for example, if an alginic acid based gel is desirable, a greater proportion of a soluble metal carbonate may be necessary as compared to the amount of alginic acid provided. Between about 1 to about 35% by weight of the tablet may be alginic acid and a stoichiometric amount, or an excess, of a carbonate radical precursor may be desirable.
The metal carbonate is, preferably, a carbonate or bicarbonate of an alkali or alkaline earth metal, such as the metal sodium, potassium, calcium, magnesium or manganese.
While aliginic acid is specifically mentioned, other in-situ gel forming acids may also be used so long as gel formation can be rapid, sufficient viscosity can be achieved and both the precursor and the resulting gel is pharmaceutically acceptable.
to See U.S. Patent No. 4,414,198. The slurry that results from the disintegration of the dosage form and exposure of the in-mouth viscosity enhancer to saliva should begin to provide sufficient viscosity to result in cohesion and an acceptable organoleptic sensation within about a minute or less of placing the dosage form in a patient s mouth. _ It will be appreciated that the disintegration of the dosage form, dissolution of selected excipients and formation of a viscous slurry does not necessarily happen all at once.
As a tablet is placed in the mouth, its outer layer is exposed.
to saliva., As the dissolvable materials dissolve and the tablet begins to disintegrate, microcapsules and/or powders are released and the viscosity enhancer begins to exert its influence helping mitigate the spread of the released drug and insoluble ingredients throughout the mouth. If a patient were to swallow while retaining the remainder of the dissolving tablet ir. their mouth, a more cohesive mass of material will be swallowed while the tablet continues its progression towards complete disintegration. of course, the tablet material can be held completely in the mouth, without swallowing, in which case a more complete integra' mass may eventually be swallowed. As each successive surface portion of the tablet is exposed to saliva, the available pool of viscous material is increased unless carried to another part of the mouth or swallowed.
WO 00/09090 PCT/US99/18d00 This process can be greatly assisted by the presence of an effervescent material. The liberating gas helps to "stir things up" assisting in the stimulation of saliva necessary for the viscosity enhancers to be effective. They also help insure proper mixing of the viscosity enhancer with the saliva and other ingredients shortening the time necessary for the viscosity enhancing material to exert its influence.
Other common excipients such as, tableting lubricants, colors, sweeteners, flavors and the like may also be included. Lubricants, such as magnesium stearate should also be included in an amount of less than about 5% by weight of the finished tablet, preferably less than about 2% and most preferably about 0.5% by weight. The same is true for other excipients.
As previously noted, an equivalent amount of powder may be used in place of microcapsules. If the powder used is uncoated, then the amount of powder utilized is equal to the amount of active ingredient in encapsulated form used in the formulation as previously described. Therefore, if a tablet was to contain '70% coated acetaminophen and the acetaminophen was to be coated with an extended release coating that made up 20% by weight of the total weight of the microcapsule, then the amount of acetaminophen powder used would be equal to the amount of acetaminophen exclusive of the coating. In this example, the resulting amou:~t of powder will make up a smaller percentage by weight of the total formulation, although the amount of acetaminophen ad;~ir.istered in each instance is about the same.
If the acetaminophen powder was coated for taste masking purposes, ther_ the amount of powder substituted for microca~_sules in the formulation would also fall within the ranges previously described with a certain percentage of the powder being coating material as described herein.
Any coating useful for taste masking, without significantly affecting the drug's dissolution properties may be used.
- WO 00/09090 PCTlUS99/18400 Preferred coatings include Opadry (Colorcon), Surelease (Colorcon), Aquacoat (FMC) and Eudragit (Rohm). Combinations and multiple layers such as a coating of Eudragit E100 is used in one layer and Surelease and Opadry are mixed to form a second layer are also contemplated.
Tablets according to the present invention can be manufactured by well-known tableting procedures. In common tableting processes, material which is to be tableted is deposited into a cavity, and one or more punch members are then l0 advanced into the cavity and brought into intimate contact with the material to be pressed, whereupon compressive force is applied. The material is thus forced into conformity with the shape of the punches and the cavity. Hundreds, and even thousands, of tablets per minute can be produced in this fashion. Various tableting methods, well known to those skilled in the art, are comprehensively discussed throughout Pharmaceutical Dosage Forms: Tablets, Second Edition, edited by Herbert A. Lieberman et al., Copyright 1989 by Marcel Dekker, Inc., as well as other well known texts. Tablets should be compressed to a hardness of between about 10 and about 50 Newtons and preferably, about 15 to about 40 Newtons.
Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. Tt is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present invention as defined by the appended claims.
A coated powder formulation of Famotidine may be prepared as ~ollows:
Ingredients Amount (g) Famotidine 500 Surelease~" Ethyl cellulose) 1600 Water 1633.33 Opadry~"(Hydroxypropyl methyl cellulose) 100 A coating solution is prepared by initially stirring Opadry in water for about 30 minutes. Then, Surelease is added to the solution and stirred further. The coating of the Famotidine is then carried out as follows. Famotidine, screened through 2o mesh, is taken for coating. The airflow during the coating is maintained at 55 CMH (cubic meters/hr) and spray rate is 21 g/min. As coating proceeds, bed volume increases and hence, the airflow also increases to about BO
CMH. The inlet air temperature is maintained at about 80 C to obtain a bed temperature of 39-41C.
Tablets can be prepared from the following formulation (Tablet Size -- 3/8" Tablet Weight 300mg):
mg/300 mg %w/w Inq-redients tablet per tablet Coated Famvtidine 40.00 13.3 Mannitol 151.10 50.4 Aspartame 15.00 5.0 Sodium Bicarbonate 9.00 3.0 Citric Acid 6.00 2.0 5 Hydroxvpropyl methyl cellulose (K15M) 30.00 10.0 Microcrystalline cellulose (Avicel) 30.00 10.0 Silicon dioxide 0.90 0.3 Crospovidone, USP 15.00 5.0 3C Magnesium Stearate, NF 3.00 1.0 TOTAL 300.00 100.0 Procedure: Weigh and screen all materials except Magnesium Stearate and blend for 30 minutes in a blender.
Then, weigh and screen Magnesium Stearate and add to above 35 blend and mix a further 5 minutes. The powder is discharged and tableted at about 15-20 Newtons.
A dosage form including microencapsules of.
P::eudoephedrine Hydrochloride may be prepared as follows:
LAYERING SOLUTION FORMULA
WO 00/09090 pC'T/US99/18400 Ingredients Amount (g) Pseudoephedrine Hydrochloride 600 Hydroxypropyl methyl cellulose(E3 Prem LV11) 11.86 Polyethylene glycol 3350 1.19 Purified water 375.02 COATING SOLUTION FORMULA
Ingredients Amount (g) Hydroxypropylmethylcellulose phthalate (HP-50) 232.5 Triethyl citrate 17.5 Ethanol 1125 Acetone 1125 The layering solution is sprayed onto inert sugar beads (Nu-core~"white beads) at a rate of 36g/min to obtain a weight gain of 200%. The airflow during the process is maintained between 60 and 48 CMH and the inlet air temperature is maintained at 65C. After layering, the beads are screened through a 30 mesh screen.
The coating solution is then sprayed onto the layered beads where the airflow is maintained at 60 CMH, and the spray rate is 21 g/min. The =nlet air temperature is maintained at 85C. Coating is carried out to obtain a weight gain of 26%.
These coated beads may then be tableted as described in the tableting procedure above.
The microcapsules are then tableted as follows (Tablet Size -- 5/8" Tablet Weight -- 700 mg):
mg/700 %w/w m~
Ingredients tablet per tablet Coated beads 161.00 23.0 Mannitol ~ 159.60 22.8 Prosolv'~ 90 (si licified microcrystalline cellulose) 20.30 2.9 Sodium Bicarbonate 84,.00 12.0 Citric Acid 56.00 8.0 Hydroxypropyl methyl cellulose (K15M) 175.00 25.0 Silicon dioxide 2.10 0.3 Crospovidone, USP 35.00 5.0 ~ 0 Magnes i.~am Stearate , NF 7 . 00 1 . 0 TOTAL 700.00 100.0 Procedure: Weigh and screen all materials except Magnesium Stearate and blend for 30 minutes in a blender.
Then, weigh and screen Magnesium Stearate and add to above blend and mix a further 5 minutes. The tablets are then compressed with this blend at about 15-20 Newtons. However, tablets can be compressed at from between 15-50 Newtons.
INDUSTRIAL APPLICABILITY
The invention is relevant to the pharmaceutical and medical industries and provides for new and useful dosage forms and methods of making same.
The present invention solves these problems by, in one aspect, providing an orally disintegrable tablet suitable for use in the delivery of sustained or extended release S formulations of coated granules, coated particles or microcapsules.
Applicants have found that a method of addressing the distasteful sensation which may accompany the use of extended or sustained release coated formulations is by providing a l0 material which will decompose or disintegrate in the mouth so as to form a relatively viscous slurry with saliva. This viscous saliva slurry will help contain the particles as a loose but cohesive mass thereby preventing the particle from distributing throughout the mouth, i.e., under the tongue, 15 between the gums and lips, etc. This therefore provides a greatly enhanced organoleptic sensation. This is accomplished by providing an in-mouth disintegrable formulation (orally disintegrating tablets, capsules, etc.) that includes an in-mouth viscosity enhancer which provides a pleasant mouth feel 20 and helps to cause the individual particles to associate with each other and with saliva to thereby incorporate the extended release particles into a salivary mass of increased viscosity.
This in turn allows the particles to stay together and glide smoothly and be easil~, swallowed. This in-mouth viscosity 25 enhancing material can be, for example, an in situ formed gel or a material such as gums or various polymers. Mixtures are also contemplated.
The tablet preferably contains between about 10 and about eo% of an extended release coated material by weight of 30 the tablet. For convenience, we will refer herein to these coated materials as "microcapsules." However, it should be urld.erstood that this term contemplates t~.~ --,.e of any extended, enteric or sustained-release vehicle, including microgranulC~, granules, microcapsules, particles, microparticles, adsorbates 35 and the like known ;in the industry. Indeed, these particulate WO OOI09090 PC'T/US99/18400 materials, referred to collectively herein as "microcapsules,"
need not necessarily be coated at all; so long as they can achieve an extended release. These microcapsules generally have a particle size ranging from between about 50 to about 3,000 microns and include between about 5 and about 70% of a coating based on the weight of the microcapsules. The coating is an extended or enteric release coating.
The tablet also generally includes between about 5 and about 60% of a rapidly dissolvable sugar or sugar alcohol l0 filler. The rapidly dissolvable sugar or sugar alcohol filler has a particle size selected to be complementary to the particle size of the microcapsules and generally ranges between about 300 and about 1,500 microns. The tablet also includes between about 0 and about 35% of a binder, including insoluble filler-binders, between about 1 and about 40% of a disintegrant; and between about 0 and about 50% of an effervescent couple. The sugar or sugar alcohol, binder disintegrant and if present, the effervescent couple are all provided in amounts based on the weight of the finished tablet.
By the use of the present invention one can develop in-mouth dis.integrable tablets which can disintegrate in the mouth in under a minute, preferably under 30 seconds. The thus disintegrated tablet releases the sustained or extended release microcapsules into the mouth. The use of .the viscosity enhancer helps to maintain the available saliva, excipients and microparticles as an integral mass. However, the resulting slurry remains both easy and pleasurable to swallow.
The present invention therefore solves the problems facing the prior art. Even with relatively large microcapsules, it is possible to obtain a dosage form which can disintegrate rapidly in the mouth and yet results in a pleasant crganoleptic mouth feel. Relatively large microcapsules can be released into the mouth without a significant amount of chewing which could break the microcapsules~ and/or alter their release 3J profile. The microcapsules are bound together, in a loose WO 00/09090 PCTlUS99/18400 confederation, which reduces this tendency to dissipate throughout the mouth oz the patient causing irritation, discomfort, and an adverse organoleptic sensation. Ideally, the pharmoco-kinetic performance of the drug administered 5 through this dosage form will not be in any way altered by a comparison of the direct administration of equal amounts of non-tableted extended release microcapsules. Again, these increased organoleptic properties, coupled with the convenience of rapid and in-mouth disintegration, greatly assists in l0 assuring compliance.
In another aspect of the present invention, closely related to that just described, the present invention provides a slurry generated in the mouth of a patient following the placement of a dosage form in the patient's mouth to serve as a binding medium to hold certain non-extended release/non-enteric coated active ingredients together as a mass which can easily be swallowed. This decreases the opportunity for the particles or powders to stick to membranes or between teeth, leaving an unpleasant mouth feel and/or unpleasant taste. Moreover, to the extent that any coated or encapsulated drug was to permeate the coating, it would encounter a viscous salivary mixture through which the dissolved drug must diffuse in order to reach the taste buds Since diffusion through the viscous medium is slow, little, if any, of the drug is tasted before it is swallowed. These various mecha:,isms improve the organoleptic properties of the medication. Of course, the use of both the extended release mic~ocaps~.:ies and powders in a single dosage form are also contemplated. This would provide both an immediate release of drug and prolonged release as well.
It will be appreciated that the term "powder" as used herein contemplates both a true powder, as well as truly crystalline materials, microgranulated and granulated materials, agglomerates, adsorbates and the like. In addition, when these powders are coated, the coating contemplated is a ~5 rapid release coating -- one which can assist in providing WO 00/09090 PC'T/US99/18400 effective taste masking while providing minimal inference with the coated active ingredient's normal dissolution profile.
Ideally these coatings will dissolve, disintegrate or become sufficiently porous to allow the full release and dissolution of the coated drug in a manner consistent with the administration of the same drug in a completely uncoated fashion. Certainly, the use of these "coated powders" should not alter the dissolution rates of the drug in the digestive tract by more than an hour and preferably by less than half an hour.
In this way, these powder materials are distinguished from "microcapsules" having extended, sustained, or enteric coatings as discussed herein. For convenience, these coated and uncoated species will be encompassed within the term "powder."
Furthermore, while the various aspects of the present invention will principally be described in terms of the use of microcapsules i.e., extended,' enteric or sustained release species, the formulations described are applicable to both 2o microcaDSUles and powders a~less noted otherwise. Therefore, for example, in a particular formulation, an equivalent amount of a powder can be substituted for an equivalent amount of microcapsules. Of course, some adjustments may be necessary to account for the relative di~ferences in the weight of the coatings used. However, the amount of uncoated drug should be eauivalent in each case.
Another aspect o~ the present invention is the discovery of an interesting synergy which exists by the use of effervescent materials in combination with the dosage forms described herein. In addition to the normal role of effervescence in stimulating the mouth's production of saliva, speeding disintegration, the aiding in taste masking, the presence of effervescence in the dosage forms of the present invention actuall,~~ enhances the overall performance of these dosage forms. it is believed that effervescence helps provide w0 00/09090 PCTlUS99/18a00 a driving force and a mixing action which increases the speed with which the viscosity of the resulting slurry is formed.
The effervescence also is believed to help carry the slurry away from the dissolving and disintegrating surface of the tablet such that the viscous slurry does not completely encapsulate same and retard further disintegration. Not a great deal of effervescence is required to obtain these results although the organoleptic properties of the dosage forms can be significantly altered based on the amount of effervescent material present.
BEST MODE OF CARRYING OUT INVENTION
In accordance with the present invention, "orally disintegrable" mear_s that the tablet will disintegrate substantially into its component parts (e. g. the powder, microcapsules and insoluble excipients, etc.) within three minutes, preferably within two minutes or less and more preferably within about one minute or less. For very large tablets, i.e., ?,500 mg or above, greater than three may be required. However, such extended disintegration time is contemplated in the phrase "substantially disintegrated."
"Dissolvable" or "dissolution," in accordance with the present invention, refers to certai:. components of the tablet of the present invention which are substantially soluble in water and saliva. At least about 500 by weight of such ingredients will dissolve and preferably within about 90 seconds of a tablet being placed in a patient's mouth.
Microcapsules in accordance with the present invention, includes active ingredients which are in the form of coated particles, microparticles, microcapsules, granules, microgranules, adsorbates, etc. and ar_e provided in an amount of between about l0 and about 80% based on the tablet's weight.
This means that between to and 80% of the weight of the finished tablet is made up of microcapsules. More preferably, the amount of microcapsules ranges from between about 20-70's by weight.
- W O 00/09090 PCTN S99/ I S.t00 These microcapsules should have a particle size ranging from between about 50 to about 3,000 microns, and more preferably between about 300 to about 2,000 microns.
Of these microcapsules, between about 5 to about 70%
by weight of the microcapsules themselves is made up of the enteric, sustained release or extended release coating.
Preferably, the amount of coating, by weight of the microcapsules, ranges from between about 10 to about 40% and more preferably from between about l0 to about 200.
The coating in accordance with the present invention is an extended or enteric release coating. By extended or enteric release it is understood that while the microcapsules are rapidly dispersed in the mouth the active ingredients or drug itself is released from the microcapsules slowly or in a manner that alters its otherwise normal release profile. By the use of these coatings, the time necessary between doses of drug can be extended relative to the use of the same quantity of uncoated particles or microcapsules. Preferably the extended release coatings in accordance with the present invention will provide for a release of drug, with as uniform a rate as possible, over a period of time ranging from between about 4 to about 48 hours and more preferably from between about 4 to about 24 hours.
Preferred extended release coatings in accordance with the present invention include, for example, cellulose ethers, cellulose esters, polymethacrylates and copolymers, polvvinylacetate copolymers. Cellulose ethers include hydroxy propylmethyl cellulose, ethyl cellulose, hydroxypropyl cellulose and sodium carboxymethyl cellulose. Cellulose esters include hydroxypropylmethyl cellulose phthalate, cellulose-acetate phthalate, and hydroxypropylmethyl cellulose acetate succinate. Polymethacrylates include methacrylic acid/methyl methacrylate copolymers, methacrylic acid-methyl acrylate copolymers and dimethyl amino-methyl methacrylate copolymers.
Pclyvin~~l acetate copolymers include vinylacetate/vinylpyrrolidone copolymers polyvinylacetate phthalate and polyvinylpyrrolidone. Enteric coatings include, without limitation, cellulose acetate phthalate, shellac, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, and a family of polymers sold under the trademark EUDRAGIT~' .
The active ingredient can include pharmaceutical ingredients, vitamins, minerals and dietary supplements.
Pharmaceutical ingredients may include, without limitation, l0 antacids, analgesics, anti-inflammatories, antipyretics antibiotics, antimicrobials, laxatives, anorexics, antihistamines, antiasthmatics, antidiuretics, anti-flatuents, antimigraine agents, biologicals (proteins, peptides, oligonueleotides, etc.) anti-spasmodics, sedatives, antihyperactives, antihypertensives, tranquilizers, decongestants, beta blockers and combinations thereof. Also encompassed by the terms "active ingredient(s),"
"pharmaceutical ingredientls)" and "active agents" are the drugs and pharmaceuticall.~~ active ingredients described in Mantelle, U.S. Patent No. 5,23,957, in columns 18 through 21.
As used in this disclosure, the term "vitamin" refers to trace organic substances that are required in the diet. For the purposes of the present invention, the term "vitamin(s)"
includes, without limitation, thiamin, riboflavin, nicotinic acid, pantothenic acid, pyridoxine, biotin, folic acid, vitamin H12, lipoic acid, ascorbic acid, vitamin A, vitamin D, vitamin E and vitamir. K. Also included within the term "vitamin" are the coenzymes thereof. Coenzymes are specific chemical forms of vitamins. Coenzymes include thiamine pyrophosphates (TPF), flavin mononucleotide (FMM), flavin adenine dinucleotide (FAD), Nicotinamide adenine dinucleotide (NAD), Nicotinamide adenine dinucleotide phosphate (NADP), Coenzyme A (CoA), pyridoxal phosphate, biocytin, tetrahydrofolic acid, coenzyme lipoyllysine, II-cis-retinal, and WO 00/09090 PC'TNS99/18400 1,25-dihydroxycholecalciferol. The term "vitamin(s)" also includes choline, carnitine, and alpha, beta, and gamma carotenes.
The term "mineral" refers to inorganic substances, 5 metals, and the like required in the human diet. Thus, the term "mineral" as used herein includes, without limitation, calcium, (calcium carbonate), iron, zinc, selenium, copper, iodine, magnesium, phosphorus, chromium and the like, and mixtures thereof. The term "dietary supplement" as used herein 10 means a substance which has an appreciable nutritional effect when administered in small amounts. Dietary supplements include, without limitation, such ingredients as bee pollen, bran, wheat germ, kelp, cod liver oil, ginseng, and fish oils, amino-acids, proteins and mixtures thereof. As will be appreciated, dietary supplements may incorporate vitamins and minerals.
In general, the amount of active ingredient incorporated in each tablet or dosage form may be selected according to known principles of pharmacy. An effective amount ?0 of pharmaceutical ingredient is specifically contemplated. By the term "effective amount," it is understood that, with respect, to for example, pharmaceuticals, a "pharmaceutically effective amount" is contemplated. A "pharmaceutically effective amount" is the amount or quantity'of a drug or pharmaceutically active substance which is sufficient to elicit the reauired or desired therapeutic response, or in other words, the amount which is suf~icient to elicit an appreciable biological response when administered to a patient. As used with reference to a vitamin or mineral, the term "effective amount" means an amount at least about 10% of the United States Recommended Daily Allowance ("RDA") of that particular ngredient for a patient. For example, if an intended ingredient is vitamin C, then an effective amount of vitamin C
would include an amount of vitamin C sufficient to provide l0%
or more of the RDA. Typically, where the tablet includes a mineral or vitamin, it will incorporate higher amounts, preferably about 100% or more of the applicable RDA.
The amount of active ingredient used can vary greatly. Of course, the size of the dosage form, the requirements of other ingredients, and the number of, for example, tablets which constitute a single dose will all impact the upper limit on the amount of pharmacologically active ingredient which can be used. However, generally, the active ingredient is provided in an amount of between greater than zero and about 80% by weight of the finished tablet and, more preferably, in a range of between greater than zero and about 60's by weight thereof. Put in other terms, the active ingredient can be included in an amount of between about 1 microgram to about 2 grams, and more preferably between about 0.01 and about 1000 milligrams per dosage form, i.e., per tablet.
Dosage forms in accordance with the present invention also includes between about S and about 600 of a rapidly dissolvable sugar or sugar alcohol filler. This amount is 2o based on the weight of the finished tablet. More preferably, the amount of such =filler will range from between about 10 to about 35% by weight based on the tablet.
Rapidly dissolvable sugar and sugar alcohol in accordance with the present invention include, for example, mannitol, lactose, sucrose, maltose, dextrose, sorbitol, xvlitol, maltitoi, iactito'~, and maltadextrins. Mannitol and other similar compou:~ds ha~,-~.na a negative heat of solution are preferred because they provide a particularly pleasant sensation enhancing the organoleptic experience of taking the tablet of the present invention. Most preferably, the filler is sucrose, mannitol, xylitol, lactose and maltose. When used at all, preferably only rapidly water soluble filler materials should be used.
WherF necessary, granulated materials are used such that the particle size of the filler is complementary to that WO 00/09090 ' pCT/US99I1840t1 of the particle size of the microcapsules. "Complementary"
does not mean that the particle sizes need be exactly the same.
However, the greater the degree of similarity, the greater the homogeneity of the material. The greater homogeneity, in turn, results in much greater uniformity of disintegration and dissolution. The particle size of the filler should therefore range from between about i00 to about 2,800 and more preferably between about 150 to about 1,540 microns.
For tableting purposes, a binder is preferred. The l0 binder should be present in an amount of between about o to about 35's by weight based on the weight of the tablet.
Preferably, the binder will be present in an amount which is greater than zero and indeed, in an amount of between about 3 to about 15x. Water soluble binders are preferred. But generally, such binders are water insoluble. Therefore, the effort should be made to minimize the content of such binders as the higher the overall content of insoluble materials such as the coated active, the lower the overall organoleptic quality of the formulation. Certain binders such as a number of insoluble filler-binders including microcrystalline cellulose sold under the trade name "AVICELT""" have additional advantageous properties that, despite their insolubility, make them nonetheless more desirable than other similar binders. A
number of AVICELT" formulations such as, for example, type PH113 available from FMC Corpora~ion, Princeton, New Jersey can act as a dry binder. However, when placed in an aqueous environment such as, ir. a patient's mouth, the binder can actually aid in the disintegration of the tablet. In addition, microcrystalline cellulose imparts an almost creamy mouth feel 3o which helps offset the negative impact of its insolubility.
The use of such binders therefore helps reduce the overall amount of disintegrant which needs be used. Other binders include alginic acid, sodium alginate, starch, modified starches and other water swellable binders. Methyl cellulose is also preferred. Note that certain binders can also be used and classified as disintegrants as is knawn in the industry.
Other disintegrants are also often desirable.
Disintegrants, such as crospovidone (cross-linked polyvinyl pyrrolidone (cross-linked "PVP")) are generally water insoluble. While they add to the rapid disintegration of the formulation, their inclusion can also add to the total content of insoluble ingredients making it more difficult to strike a balance between disintegration/dissolution speed and the resulting organoleptic sensation. Preferably, the amount of disintegrant will range from between greater than zero, i.e., about 1 to about 40% by weight based on the weight of the tablet and more preferably between about 3 to about 20%. Other disintegrants useful include sodium starch glycolate, croscarmallose sodium, microcrystalline cellulose and starch.
An effervescent couple is also preferred for use in accordance with the present invention. When present at all, it can be provided in a relatively small amount. The effervescent couple provides a number of advantages in the overall context of the present formulation. First, it aids in the disintegration of the tablet making it easier for the dissolvable constituents to dissolve and rapidly create a slurry. The presence of effervescence can also help stimulate the generation o~ saliva again facilitating disintegration, dissolution and the formation of an in-mouth slurry. Finally, many find the sensation o~ a mild amount of effervescence to be pleasing and this helps fac,~~itate compliance by enhancing the organoleptic properties of the tablet.
The term effervescent couples) includes compounds which evolve gas. The preferred effervescent couples evolve gas by means of chemical reactions which take place upon exposure of the effervescent couple to water and/or to saliva in the mouth. The bubble or gas generating reaction is most often the result of the reaction of a soluble acid source and alkali metal carbonate or carbonate source. The reaction of these two general classes of compounds produces carbon dioxide gas upon contact with water included in saliva.
Such water activated materials should be kept in a generally anhydrous state with little or no absorbed moisture or in a stable hydrated form since exposure to water will prematurely disintegrate the tablet. The acid sources or acid may generally include food acids, acid anhydrides and acid salts. Food acids include citric acid, tartaric acid, malic acid, fumaric acid, adipic acid and succinic acids, etc.
to Because these acids are directly ingested, their overall solubility in water is less important than it would be if the effervescent tablet formulations of the present invention were intended to be dissolved in a glass of water. Acids, anhydrides and salts may be used. Salts may include sodium, dihydrogen phosphate, disodium dihydrogen pyrophosphate, acid citrate salts and sodium acid sulfite.
Carbonate sources include dry solid carbonate and bicarbonate salts such as sodium bicarbonate, sodium carbonate, potassium bicarbonate and potassium carbonate, magnesium 2o carbonate and sodium sesquicarbonate, sodium glycine carbonate, L-lysine carbonate, arginine carbonate and amorphous calcium carbonate.
The effervescent couple of the present invention is not always based upon a reaction which forms carbon dioxide.
Reactants which evolve oxygen or other gases which are safe are also considered within the scope. Where the effervescent couple includes two mutually reactive components, such as an acid source and a carbonate source, it is preferred that both components react completely. Therefore, an equivalent ratio of components which provides for equal equivalents is preferred.
For example, if the acid used is diprotic, then either twice tire amount of a mono-reactive carbonate base, or an equal amount of a di-reactive base should be used for complete neutralization to be realized. However, in other embodiments of the present invention, the amount of either acid or WO 00/09090 PCT/US99/18.100 carbonate source may exceed the amount of the other component.
This may be useful to enhance taste and/or performance of a tablet containing an overage of either component. In this case, it is acceptable that the additional amount of either 5 component may remain unreacted. It may be desirable to add an excess of one component in order that the excess may react with an in situ gel forming substance. An example of this is an excess of sodium bicarbonate to react with alginic acid to form a gel.
l0 In general, the effervescent couple may be provided in an amount of between greater than zero to about 50% by weight of the tablet. More preferably, it will be provided in an amount of greater than zero to about 350. It is preferred, however, that the effervescent Couple be provided in an amount 15 which is greater than zero. Indeed, while neither a binder nor an effervescent couple is required to provide acceptable performance, the use of at least one of a binder and/or effervescent couple is preferred. Most preferably, some amount of both are provided. An effervescent couple may not be needed when certain in-mouth viscosity enhancers are used. In other instances, the liberated gas in conjunction with the viscosity enhance. results in a slurry of the required viscosity.
The in-mouth viscosity enhancer or viscosity modifiers in accordance witr: the present invention can include gels, in-situ gel formers, gums and polymeric materials. The in-mouth viscosit~~ enhancing material may include, for example, in-situ gel Dormers such as alginic acid and a complimentary soluble metal carbonate, a gum such as arabic, xanthan, guar, etc. and carbopolvmers such as carbopols available from Croda, Inc., hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, etc. Most preferred are ~;ethv lce'.lules~ , i-v:~;:roy~propylmethyl cellulose , hydroxyethyl cellulose, carbolpol and silicon dioxide. These materials are provided in an amount which is sufficient to increase the viscosity oI the slurry that results from the disintegration WO 00/09090 PC'T/US99/18400 and dissolution of the various other components of the tablet in a patient's mouth. However, the amount of such in-mouth viscosity enhancing ingredients must be controlled to ensure that an organoleptically acceptable slurry results and that the increased viscosity does not too adversely affect either the in-mouth disintegration time or the organoleptic properties of the formulation.
The amount of these viscosity enhancers used to provide sufficient cohesion and form an organoleptically l0 acceptable (i.e. one which is palatable and preferably pleasant) slurry will vary greatly depending upon a number of factors including the volume of medicine to be delivered, the type of patient (the viscosity may need to be different for children than for adults) the disintegration time and the specific type of viscosity enhancer used. The amount used will be that which provides an effective amount of viscosity to the slurry resulting from the disintegration of the dosage form, the dissolution of the saliva dissolvable species and the release of the insoluble species. Generally, the amount of viscosity enhancer will range from between about 1 and about 36~ by weight and more preferably between about 2 and about 200. In any event, sufficient viscosity enhancers should be used to provide effective viscosity enhancement. This means that the resulting viscosit;,- of the slurry should range from between 25,000 to 500,000 (centipoise) CPS and more preferably between about 25,000 and about 300,000 CPS.
A lesser amount of a gum, for example, may be necessary than the amount of components necessary for the in-situ formation of a gel. It may also be necessary to include the varying proportions of viscosity modifiers. Thus, for example, if an alginic acid based gel is desirable, a greater proportion of a soluble metal carbonate may be necessary as compared to the amount of alginic acid provided. Between about 1 to about 35% by weight of the tablet may be alginic acid and a stoichiometric amount, or an excess, of a carbonate radical precursor may be desirable.
The metal carbonate is, preferably, a carbonate or bicarbonate of an alkali or alkaline earth metal, such as the metal sodium, potassium, calcium, magnesium or manganese.
While aliginic acid is specifically mentioned, other in-situ gel forming acids may also be used so long as gel formation can be rapid, sufficient viscosity can be achieved and both the precursor and the resulting gel is pharmaceutically acceptable.
to See U.S. Patent No. 4,414,198. The slurry that results from the disintegration of the dosage form and exposure of the in-mouth viscosity enhancer to saliva should begin to provide sufficient viscosity to result in cohesion and an acceptable organoleptic sensation within about a minute or less of placing the dosage form in a patient s mouth. _ It will be appreciated that the disintegration of the dosage form, dissolution of selected excipients and formation of a viscous slurry does not necessarily happen all at once.
As a tablet is placed in the mouth, its outer layer is exposed.
to saliva., As the dissolvable materials dissolve and the tablet begins to disintegrate, microcapsules and/or powders are released and the viscosity enhancer begins to exert its influence helping mitigate the spread of the released drug and insoluble ingredients throughout the mouth. If a patient were to swallow while retaining the remainder of the dissolving tablet ir. their mouth, a more cohesive mass of material will be swallowed while the tablet continues its progression towards complete disintegration. of course, the tablet material can be held completely in the mouth, without swallowing, in which case a more complete integra' mass may eventually be swallowed. As each successive surface portion of the tablet is exposed to saliva, the available pool of viscous material is increased unless carried to another part of the mouth or swallowed.
WO 00/09090 PCT/US99/18d00 This process can be greatly assisted by the presence of an effervescent material. The liberating gas helps to "stir things up" assisting in the stimulation of saliva necessary for the viscosity enhancers to be effective. They also help insure proper mixing of the viscosity enhancer with the saliva and other ingredients shortening the time necessary for the viscosity enhancing material to exert its influence.
Other common excipients such as, tableting lubricants, colors, sweeteners, flavors and the like may also be included. Lubricants, such as magnesium stearate should also be included in an amount of less than about 5% by weight of the finished tablet, preferably less than about 2% and most preferably about 0.5% by weight. The same is true for other excipients.
As previously noted, an equivalent amount of powder may be used in place of microcapsules. If the powder used is uncoated, then the amount of powder utilized is equal to the amount of active ingredient in encapsulated form used in the formulation as previously described. Therefore, if a tablet was to contain '70% coated acetaminophen and the acetaminophen was to be coated with an extended release coating that made up 20% by weight of the total weight of the microcapsule, then the amount of acetaminophen powder used would be equal to the amount of acetaminophen exclusive of the coating. In this example, the resulting amou:~t of powder will make up a smaller percentage by weight of the total formulation, although the amount of acetaminophen ad;~ir.istered in each instance is about the same.
If the acetaminophen powder was coated for taste masking purposes, ther_ the amount of powder substituted for microca~_sules in the formulation would also fall within the ranges previously described with a certain percentage of the powder being coating material as described herein.
Any coating useful for taste masking, without significantly affecting the drug's dissolution properties may be used.
- WO 00/09090 PCTlUS99/18400 Preferred coatings include Opadry (Colorcon), Surelease (Colorcon), Aquacoat (FMC) and Eudragit (Rohm). Combinations and multiple layers such as a coating of Eudragit E100 is used in one layer and Surelease and Opadry are mixed to form a second layer are also contemplated.
Tablets according to the present invention can be manufactured by well-known tableting procedures. In common tableting processes, material which is to be tableted is deposited into a cavity, and one or more punch members are then l0 advanced into the cavity and brought into intimate contact with the material to be pressed, whereupon compressive force is applied. The material is thus forced into conformity with the shape of the punches and the cavity. Hundreds, and even thousands, of tablets per minute can be produced in this fashion. Various tableting methods, well known to those skilled in the art, are comprehensively discussed throughout Pharmaceutical Dosage Forms: Tablets, Second Edition, edited by Herbert A. Lieberman et al., Copyright 1989 by Marcel Dekker, Inc., as well as other well known texts. Tablets should be compressed to a hardness of between about 10 and about 50 Newtons and preferably, about 15 to about 40 Newtons.
Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. Tt is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present invention as defined by the appended claims.
A coated powder formulation of Famotidine may be prepared as ~ollows:
Ingredients Amount (g) Famotidine 500 Surelease~" Ethyl cellulose) 1600 Water 1633.33 Opadry~"(Hydroxypropyl methyl cellulose) 100 A coating solution is prepared by initially stirring Opadry in water for about 30 minutes. Then, Surelease is added to the solution and stirred further. The coating of the Famotidine is then carried out as follows. Famotidine, screened through 2o mesh, is taken for coating. The airflow during the coating is maintained at 55 CMH (cubic meters/hr) and spray rate is 21 g/min. As coating proceeds, bed volume increases and hence, the airflow also increases to about BO
CMH. The inlet air temperature is maintained at about 80 C to obtain a bed temperature of 39-41C.
Tablets can be prepared from the following formulation (Tablet Size -- 3/8" Tablet Weight 300mg):
mg/300 mg %w/w Inq-redients tablet per tablet Coated Famvtidine 40.00 13.3 Mannitol 151.10 50.4 Aspartame 15.00 5.0 Sodium Bicarbonate 9.00 3.0 Citric Acid 6.00 2.0 5 Hydroxvpropyl methyl cellulose (K15M) 30.00 10.0 Microcrystalline cellulose (Avicel) 30.00 10.0 Silicon dioxide 0.90 0.3 Crospovidone, USP 15.00 5.0 3C Magnesium Stearate, NF 3.00 1.0 TOTAL 300.00 100.0 Procedure: Weigh and screen all materials except Magnesium Stearate and blend for 30 minutes in a blender.
Then, weigh and screen Magnesium Stearate and add to above 35 blend and mix a further 5 minutes. The powder is discharged and tableted at about 15-20 Newtons.
A dosage form including microencapsules of.
P::eudoephedrine Hydrochloride may be prepared as follows:
LAYERING SOLUTION FORMULA
WO 00/09090 pC'T/US99/18400 Ingredients Amount (g) Pseudoephedrine Hydrochloride 600 Hydroxypropyl methyl cellulose(E3 Prem LV11) 11.86 Polyethylene glycol 3350 1.19 Purified water 375.02 COATING SOLUTION FORMULA
Ingredients Amount (g) Hydroxypropylmethylcellulose phthalate (HP-50) 232.5 Triethyl citrate 17.5 Ethanol 1125 Acetone 1125 The layering solution is sprayed onto inert sugar beads (Nu-core~"white beads) at a rate of 36g/min to obtain a weight gain of 200%. The airflow during the process is maintained between 60 and 48 CMH and the inlet air temperature is maintained at 65C. After layering, the beads are screened through a 30 mesh screen.
The coating solution is then sprayed onto the layered beads where the airflow is maintained at 60 CMH, and the spray rate is 21 g/min. The =nlet air temperature is maintained at 85C. Coating is carried out to obtain a weight gain of 26%.
These coated beads may then be tableted as described in the tableting procedure above.
The microcapsules are then tableted as follows (Tablet Size -- 5/8" Tablet Weight -- 700 mg):
mg/700 %w/w m~
Ingredients tablet per tablet Coated beads 161.00 23.0 Mannitol ~ 159.60 22.8 Prosolv'~ 90 (si licified microcrystalline cellulose) 20.30 2.9 Sodium Bicarbonate 84,.00 12.0 Citric Acid 56.00 8.0 Hydroxypropyl methyl cellulose (K15M) 175.00 25.0 Silicon dioxide 2.10 0.3 Crospovidone, USP 35.00 5.0 ~ 0 Magnes i.~am Stearate , NF 7 . 00 1 . 0 TOTAL 700.00 100.0 Procedure: Weigh and screen all materials except Magnesium Stearate and blend for 30 minutes in a blender.
Then, weigh and screen Magnesium Stearate and add to above blend and mix a further 5 minutes. The tablets are then compressed with this blend at about 15-20 Newtons. However, tablets can be compressed at from between 15-50 Newtons.
INDUSTRIAL APPLICABILITY
The invention is relevant to the pharmaceutical and medical industries and provides for new and useful dosage forms and methods of making same.
Claims (40)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A dosage form which disintegrates in the mouth of a patient comprising: at least one active ingredient in the form of a powder or microcapsule and in an amount which is sufficient to elicit therapeutic response; a filler; and at least one in-mouth viscosity enhancing material in an amount which is effective to provide an organoleptically acceptable viscous slurry having a viscosity range from between about 25,000 and about 500,000 CPS upon the disintegration of the dosage form in a patients mouth.
2. The dosage form of claim 1, wherein the microcapsule comprises an enteric, sustained release or extended release coating.
3. The dosage form of claims 1 or 2 wherein the viscosity of said organoleptically acceptable slurry ranges from between about 25,000 and about 300,000 CPS.
4. The dosage form of claim 1 wherein said in-mouth viscosity enhancing material is provided in an amount of about 1 to about 36% by weight based on the weight of the finished dosage form.
5. The dosage form of claim 4 wherein said in-mouth viscosity enhancing material is provided in an amount of about 2 to about 20% by weight based on the weight of the finished dosage form.
6. The dosage form of claim 1 wherein said in-mouth viscosity enhancing material is provided in an amount of about 1 to about 36% by weight based on the weight of the finished dosage form.
7. The dosage form of claim 2 wherein said active ingredient is provided in an amount of between about 1 microgram and about 2 grams based on the weight of said microcapsule without said coating.
8. The dosage form of claim 7 wherein said active ingredient is provided in an amount of between about 0.01 and about 1000 milligrams based on the weight of microcapsule without said coating.
9. The dosage forms of any of claims 1 to 8 wherein said filler is a rapidly dissolvable sugar or sugar alcohol.
10. The dosage form of claim 9 wherein said filler is provided in an amount of between about 5 and about 60% by weight based on the weight of the finished dosage form.
11. The dosage form of claim 10 wherein said filler is provided in an amount of between about 10 and about 35% by weight based on the weight of the finished dosage form.
12. The dosage form of any one of claims 1 to 11 further comprising at least one binder.
13. The dosage form of claim 12 wherein said binder is present in an amount of between about greater than zero and about 35%
by weight based on the weight of the finished dosage form.
by weight based on the weight of the finished dosage form.
14. The dosage form of claim 13 wherein said binder is present in an amount of between about 3 and about 15% by weight based on the weight of the finished dosage form.
15. The dosage form of claim 12 wherein said binder is water soluble.
16. The dosage form of any one of claims 1 to 15 further comprising at least one disintegrant.
17. The dosage form of claim 16 wherein said disintegrant is present in an amount of between about greater than zero and about 40% by weight based on the weight of the finished dosage form.
18. The dosage form of claims 16 or 17 wherein said disintegrant is present in an amount of between about 3 and about 20% by weight based on the weight of the finished dosage form.
19. The dosage form of claim 18 wherein said disintegrant is water soluble.
20. The dosage form of any one of claims 1 to 19 further comprising at least one effervescent couple.
21. The dosage form of claim 20 wherein said effervescent couple is present in an amount of between about greater than zero and about 50% by weight based on the weight of the finished dosage form.
22. The dosage form of claims 16, 17, 18 or 19 wherein said disintegrant is present in an amount of between about greater than zero and about 35% by weight based on the weight of the finished dosage form.
23. A dosage form which disintegrates in the mouth of a patient comprising: at least one active ingredient in the form of a powder or microcapsule and in an amount which is sufficient to elicit therapeutic response; a filler; and at least one in-mouth viscosity enhancing material in an amount which is effective to provide an organoleptically acceptable viscous slurry having a viscosity range from between about 25,000 and about 500,000 CPS upon the disintegration of the dosage form in a patients mouth and at least one effervescent couple.
24. The dosage form of claim 23 wherein said effervescent couple is present in an amount of between about greater than zero and about 50% by weight based on the weight of the finished dosage form.
25. The dosage form of claim 24 wherein said effervescent couple is present in an amount of between about greater than zero and about 35% by weight based on the weight of the finished dosage form.
26. The dosage form of claims 23, 24 or 25, wherein the microcapsule comprises an extended release coating and wherein said extended release coating comprises cellulose ethers, cellulose esters, polymethacrylates and copolymers, polyvinyl acetate copolymer.
27. The dosage form of claim 25 wherein the viscosity of said organoleptically acceptable slurry ranges from between about 25,000 and about 300,000 CPS.
28. The dosage form of claim 23 wherein said in-mouth viscosity enhancing material is provided in an amount of about 1 to about 36% by weight based on the weight of the finished dosage form.
29. The dosage form of claim 28 wherein said in-mouth viscosity enhancing material is provided in an amount of about 2 to about 20% by weight based on the weight of the finished dosage form.
30. The dosage form of claim 26 wherein said active ingredient is provided in an amount of between about 1 microgram and about 2 grams based on the weight of microcapsule without said coating.
31. The dosage form of claim 30 wherein said active ingredient is provided in an amount of between about 0.01 and about 1000 milligrams based on the weight of microcapsule without said coating.
32. The dosage form of any one of claims 1 to 31 wherein said in-mouth viscosity enhancing material is selected from the group consisting of methylcellulose, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, carbopol and silicon dioxide.
33. The dosage form of any of claims 1 to 32 wherein said microcapsules or powder have a particle size ranging from between about 50 to about 3000 microns.
34. An orally disintegrable tablet suitable for use in the delivery of at least one active ingredient in the form of microcapsules or powders comprising: between about 10 and about 80% of said active ingredient containing microcapsules or powders by weight based on the weight of the tablet, said microcapsules or powder having a particle size ranging from between about 50 to about 3,000 microns, an amount of at least one in-mouth viscosity enhancer, which is sufficient to provide a viscous, swallowable, organoleptically acceptable mass containing said microcapsules, within about 3 minutes when placed in a patients mouth, said in-mouth viscosity enhancer being selected from the group consisting of methylcellulose, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, carbopol and silicon dioxide, said organoleptically acceptable mass having a viscosity range from between about 25,000 and about 500,000 CPS; between 0 and about 60% of a rapidly dissolvable sugar or sugar alcohol filler by weight of the tablet selected from the group consisting of sucrose, mannitol, xylitol, lactose and maltose; between 0 and about 35% of a binder by weight of the tablet selected from the group consisting of microcrystalline cellulose and methyl cellulose; between 0 and about 40% of a disintegrant by weight based on the weight of the tablet selected from the group consisting of sodium starch glycolate and crospovidone; and between 0 and about 50% of an effervescent couple based on the weight of the tablet wherein said effervescent couple is present and is present in an amount of between about greater than zero and about 50% by weight based on the weight of the finished dosage form.
35. The dosage form of claim 34 wherein said effervescent couple is present in an amount of between about greater than zero and about 35% by weight based on the weight of the finished dosage form.
36. The dosage form of claim 35 wherein the viscosity of said organoleptically acceptable mass ranges from between about 25,000 and about 300,000 CPS.
37. The dosage form of claim 34 wherein said in-mouth viscosity enhancing material is provided in an amount of about 1 to about 36% by weight based on the weight of the finished dosage form.
38. The dosage form of claim 37 wherein said in-mouth viscosity enhancing material is provided in an amount of about 2 to about 20% by weight based on the weight of the finished dosage form.
39. The dosage form of claim 34 wherein said active ingredient is provided in an amount of between about 1 microgram and about 2 grams.
40. The dosage form of claim 39 wherein said active ingredient is provided in an amount of between about 0.01 and about 1000 milligrams.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9626598P | 1998-08-12 | 1998-08-12 | |
| US60/096,265 | 1998-08-12 | ||
| US09/372,738 | 1999-08-11 | ||
| US09/372,738 US6368625B1 (en) | 1998-08-12 | 1999-08-11 | Orally disintegrable tablet forming a viscous slurry |
| PCT/US1999/018400 WO2000009090A1 (en) | 1998-08-12 | 1999-08-12 | Orally disintegrable tablet forming a viscous slurry |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2339992A1 CA2339992A1 (en) | 2000-02-24 |
| CA2339992C true CA2339992C (en) | 2006-01-03 |
Family
ID=26791503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002339992A Expired - Fee Related CA2339992C (en) | 1998-08-12 | 1999-08-12 | Orally disintegrable tablet forming a viscous slurry |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6368625B1 (en) |
| EP (1) | EP1104288B1 (en) |
| JP (1) | JP2002522471A (en) |
| AT (1) | ATE326951T1 (en) |
| AU (1) | AU742049B2 (en) |
| CA (1) | CA2339992C (en) |
| DE (1) | DE69931498T2 (en) |
| ES (1) | ES2265188T3 (en) |
| WO (1) | WO2000009090A1 (en) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
| EP0974366B1 (en) | 1997-03-28 | 2006-10-18 | Eisai Co., Ltd. | Oral pharmaceutical preparations decreased in bitterness by masking |
| US20030118645A1 (en) * | 1998-04-29 | 2003-06-26 | Pather S. Indiran | Pharmaceutical compositions for rectal and vaginal administration |
| US6974590B2 (en) * | 1998-03-27 | 2005-12-13 | Cima Labs Inc. | Sublingual buccal effervescent |
| US20030091629A1 (en) * | 1998-03-27 | 2003-05-15 | Cima Labs Inc. | Sublingual buccal effervescent |
| SE9802973D0 (en) | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
| EP2269587A1 (en) | 1999-10-29 | 2011-01-05 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| ATE437632T1 (en) * | 2000-03-01 | 2009-08-15 | Eisai R&D Man Co Ltd | RAPID DISRUPTING POLYVINYL TABLET |
| JP4698000B2 (en) * | 2000-06-27 | 2011-06-08 | 旭化成ケミカルズ株式会社 | Easily water-soluble drug-containing tablets |
| AU2738302A (en) | 2000-10-30 | 2002-05-15 | Euro Celtique Sa | Controlled release hydrocodone formulations |
| US7799342B2 (en) * | 2000-12-06 | 2010-09-21 | Wyeth Llc | Fast dissolving tablet |
| US9358214B2 (en) * | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
| EP1509208A1 (en) * | 2002-02-04 | 2005-03-02 | Ranbaxy Laboratories Limited | Hydrodynamically balancing oral drug delivery system with biphasic release |
| GB0203984D0 (en) * | 2002-02-20 | 2002-04-03 | Mach Ind Etablissements | Comsumable container |
| SI21221A (en) * | 2002-06-21 | 2003-12-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Quickly decomposable tablets |
| GB0217056D0 (en) * | 2002-07-23 | 2002-08-28 | Ass Octel | Use |
| DE10244504A1 (en) * | 2002-09-25 | 2004-04-08 | Capsulution Nanoscience Ag | Quick-release dosage form with poorly soluble active ingredient |
| US8367111B2 (en) * | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
| US20040166162A1 (en) * | 2003-01-24 | 2004-08-26 | Robert Niecestro | Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid |
| NZ542303A (en) * | 2003-03-14 | 2008-12-24 | Nirmal Mulye | A process for preparing sustained release tablets |
| DE10311585A1 (en) * | 2003-03-14 | 2004-09-23 | Basf Ag | Adsorbates for use in human or animal nutrition or cosmetics are produced by introducing material to be adsorbed together with stabilizer on to carrier |
| US20070092583A1 (en) * | 2003-04-30 | 2007-04-26 | Tim Clarot | Cold remedy composition comprising zinc salts |
| CN1819819B (en) | 2003-05-07 | 2011-03-09 | 株式会社三养社 | Highly plastic granules for making fast melting tablets |
| US20040265373A1 (en) * | 2003-06-27 | 2004-12-30 | David Wynn | Soft tablet containing high molecular weight cellulosics |
| US20040265372A1 (en) | 2003-06-27 | 2004-12-30 | David Wynn | Soft tablet containing high molecular weight cellulosics |
| CA2531637A1 (en) * | 2003-07-23 | 2005-02-03 | L. Perrigo Company | Cellulosic fiber containing composition |
| US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
| CN1913876B (en) * | 2003-12-09 | 2013-06-26 | 大日本住友制药株式会社 | Drug-containing grains and solid preparation containing the grains |
| MXPA06007453A (en) * | 2003-12-31 | 2007-01-31 | Cima Labs Inc | Effervescent oral opiate dosage form. |
| DE602004031462D1 (en) * | 2003-12-31 | 2011-03-31 | Cima Labs Inc | GENERAL LINEAR SHELL FORM OF FENTANYL FOR ORAL USE AND METHOD OF ADMINISTRATION |
| US20070036853A1 (en) * | 2003-12-31 | 2007-02-15 | Cima Labs Inc. | Generally linear effervescent oral fentanyl dosage form and methods of administering |
| US7858121B2 (en) * | 2003-12-31 | 2010-12-28 | Cima Labs, Inc. | Effervescent oral fentanyl dosage form and methods of administering fentanyl |
| US20050170014A1 (en) * | 2004-01-30 | 2005-08-04 | Anandi Krishnan | Carbonyl iron pharmaceutical dosage forms for the treatment of iron-deficiency anemia |
| WO2005074658A2 (en) * | 2004-01-30 | 2005-08-18 | Glenmark Pharmaceuticals Inc., Usa | Carbonyl iron pharmaceutical dosage forms for the treatment of iron-deficiency anemia |
| KR20140104986A (en) * | 2004-02-17 | 2014-08-29 | 트랜스셉트 파마슈티칼스, 인코포레이티드 | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
| US20060003003A1 (en) * | 2004-06-28 | 2006-01-05 | Bakker Johan A | Oral sustained release formulation of tedisamil with gastric retention properties |
| US7780981B2 (en) | 2004-09-13 | 2010-08-24 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
| US8747895B2 (en) * | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
| EP2417969A1 (en) | 2004-10-21 | 2012-02-15 | Aptalis Pharmatech, Inc. | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
| US20060105038A1 (en) * | 2004-11-12 | 2006-05-18 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions prepared by coacervation |
| EP2098225B8 (en) * | 2005-01-06 | 2011-06-22 | Cima Labs Inc. | Taste masking system for non-plasticizing drugs |
| US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
| US20070123562A1 (en) * | 2005-05-25 | 2007-05-31 | Transoral Pharmaceuticals, Inc. | Compositions and methods for treating middle-of-the-night insomnia |
| US20070287740A1 (en) * | 2005-05-25 | 2007-12-13 | Transcept Pharmaceuticals, Inc. | Compositions and methods of treating middle-of-the night insomnia |
| US20070225322A1 (en) * | 2005-05-25 | 2007-09-27 | Transoral Pharmaceuticals, Inc. | Compositions and methods for treating middle-of-the night insomnia |
| WO2013059629A1 (en) | 2011-10-21 | 2013-04-25 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
| WO2011109340A1 (en) | 2010-03-01 | 2011-09-09 | Nova Southeastern University | Epinephrine nanop articles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
| US20160045457A1 (en) | 2005-09-09 | 2016-02-18 | Ousama Rachid | Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine |
| TW200800142A (en) * | 2005-09-09 | 2008-01-01 | Univ Manitoba | Fast-disintegrating epinephrine tablets for buccal or sublingual administration |
| US9877921B2 (en) | 2005-09-09 | 2018-01-30 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
| JP2009514878A (en) * | 2005-11-03 | 2009-04-09 | レッドポイント バイオ コーポレイション | Hydrazine derivatives and uses thereof |
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US7811604B1 (en) | 2005-11-14 | 2010-10-12 | Barr Laboratories, Inc. | Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same |
| US7427414B2 (en) * | 2006-01-18 | 2008-09-23 | Astron Research Limited | Modified release oral dosage form using co-polymer of polyvinyl acetate |
| US20070281014A1 (en) * | 2006-06-01 | 2007-12-06 | Cima Labs, Inc. | Prednisolone salt formulations |
| WO2007143676A2 (en) * | 2006-06-05 | 2007-12-13 | Verus Pharmaceuticals, Inc. | Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms |
| TW200816985A (en) * | 2006-06-05 | 2008-04-16 | Verus Pharmaceuticals Inc | Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies |
| US20080069891A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
| RU2009101298A (en) * | 2006-08-22 | 2010-09-27 | Рэдпойнт Био Корпорэйшн (Us) | HETEROCYCLIC COMPOUNDS AS AMPLIFIERS AMPLIFIERS |
| US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
| US20080070865A1 (en) * | 2006-09-15 | 2008-03-20 | Redpoint Bio Corporation | Triphenylphosphine oxide derivatives and uses thereof |
| WO2008057300A2 (en) * | 2006-10-27 | 2008-05-15 | Redpoint Bio Corporation | Trpvi antagonists and uses thereof |
| WO2008079245A2 (en) * | 2006-12-20 | 2008-07-03 | Duramed Pharmaceuticals, Inc. | Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof |
| WO2008097504A2 (en) * | 2007-02-02 | 2008-08-14 | Redpoint Bio Corporation | Use of a trpm5 inhibitor to regulate insulin and glp-1 release |
| US20100010031A1 (en) * | 2007-02-09 | 2010-01-14 | Yum Ii Su | Transoral dosage forms comprising sufentanil and naloxone |
| EP1977746B8 (en) | 2007-04-02 | 2014-09-24 | Parkinson's Institute | Methods and compositions for reduction of side effects of therapeutic treatments |
| EA201070715A1 (en) | 2007-12-20 | 2011-02-28 | Тева Вимен'С Хелс, Инк. | DOSING MODES, PHARMACEUTICAL COMPOSITIONS AND PACKAGES FOR EMERGENCY CONTRACEPTION |
| CA2750216A1 (en) * | 2008-12-15 | 2010-07-08 | Fleming And Company, Pharmaceuticals | Rapidly dissolving vitamin formulation and methods of using the same |
| US20100163805A1 (en) * | 2008-12-31 | 2010-07-01 | Youngtack Shim | Agent-containing media and methods therefor |
| CA2765033C (en) * | 2009-06-12 | 2020-07-14 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
| BR112012004854A2 (en) | 2009-09-04 | 2015-09-01 | Redpoint Bio Corp | A method for enhancing a sweet taste of a carbohydrate sweetener, for decreasing the amount of a carbohydrate sweetener in a consumable product, and for enhancing the sweetening of a consumable product. |
| EP2480097A1 (en) | 2009-09-22 | 2012-08-01 | Redpoint Bio Corporation | Novel polymorphs of rebaudioside c and methods for making and using the same |
| CA2782285A1 (en) | 2009-12-02 | 2011-06-09 | Luigi Mapelli | Fexofenadine microcapsules and compositions containing them |
| WO2011085181A1 (en) * | 2010-01-08 | 2011-07-14 | Eurand, Inc. | Taste masked topiramate composition and an orally disintegrating tablet comprising the same |
| EP2568977A1 (en) | 2010-05-11 | 2013-03-20 | Cima Labs Inc. | Alcohol-resistant metoprolol-containing extended- release oral dosage forms |
| WO2013006643A1 (en) | 2011-07-06 | 2013-01-10 | The Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
| EP2742126B1 (en) | 2011-08-08 | 2018-11-07 | International Flavors & Fragrances Inc. | Compositions and methods for the biosynthesis of vanillin or vanillin beta-d-glucoside |
| CA2876883C (en) | 2012-06-15 | 2022-11-01 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
| WO2014145699A1 (en) * | 2013-03-15 | 2014-09-18 | New Jersey Institute Of Technology | System and method for fabrication of uniform polymer films containing nano and micro particles via continuous drying process |
| DK2976072T3 (en) | 2013-03-22 | 2021-08-16 | Univ Nova Southeastern | EPINEPHRIN FINE PARTICLES AND METHODS OF USING IT FOR THE TREATMENT OF CONDITIONS RESPONDING TO EPINEPHRIN |
| WO2015070131A1 (en) * | 2013-11-11 | 2015-05-14 | Forest Laboratories Holdings Limited | Compositions and methods of treatment comprising fosfomycin disodium |
| EP2880992A3 (en) | 2013-12-05 | 2015-06-17 | International Flavors & Fragrances Inc. | Rebaudioside C and its stereoisomers as natural product sweetness enhancers |
| US10213586B2 (en) | 2015-01-28 | 2019-02-26 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
| AU2016228779A1 (en) | 2015-03-12 | 2017-09-07 | Chrono Therapeutics Inc. | Craving input and support system |
| US10143687B2 (en) | 2016-04-11 | 2018-12-04 | Neurocea, LLC | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases |
| US10292977B2 (en) | 2016-04-11 | 2019-05-21 | Neurocea, LLC | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases |
| JP2020503950A (en) | 2017-01-06 | 2020-02-06 | クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | Device and method for transdermal drug delivery |
| CA3101966A1 (en) | 2018-05-29 | 2019-12-05 | Morningside Venture Investments Limited | Drug delivery methods and systems |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3011950A (en) | 1959-05-19 | 1961-12-05 | Colgate Palmolive Co | Liquid composition containing discrete gaseous bodies |
| US3142621A (en) | 1961-11-02 | 1964-07-28 | Ciba Geigy Corp | Alginate suspensions of oral pharmaceutical compositions with improved taste qualities |
| US3456049A (en) | 1965-05-25 | 1969-07-15 | Ciba Geigy Corp | Gradual-release tablet |
| US3885027A (en) * | 1971-04-12 | 1975-05-20 | West Laboratories Inc | Orally administered drug composition for therapy in the treatment of narcotic drug addiction |
| DE2530563C2 (en) | 1975-07-09 | 1986-07-24 | Bayer Ag, 5090 Leverkusen | Analgesic drugs with reduced potential for abuse |
| US4414198A (en) | 1982-04-23 | 1983-11-08 | Joseph Michaelson | Rapidly disintegrable tablet composition and method |
| US4454110A (en) | 1982-05-24 | 1984-06-12 | Forsyth Dental Infirmary For Children | Self-gelling liquid composition for topical application in the oral cavity |
| US4963367A (en) | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
| JPS6124516A (en) | 1984-07-12 | 1986-02-03 | Fujisawa Pharmaceut Co Ltd | Long active tablet |
| US4610870A (en) | 1984-10-05 | 1986-09-09 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| GB8426152D0 (en) | 1984-10-16 | 1984-11-21 | Reckitt & Colmann Prod Ltd | Medicinal compositions |
| US5288497A (en) | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
| US4687662A (en) * | 1985-08-30 | 1987-08-18 | Warner-Lambert Company | Therapeutic effervescent composition |
| US4710384A (en) | 1986-07-28 | 1987-12-01 | Avner Rotman | Sustained release tablets made from microcapsules |
| US5624683A (en) | 1986-08-06 | 1997-04-29 | Eisai Co., Ltd. | Sustained-release multi-granule tablet |
| US5288500A (en) | 1987-03-13 | 1994-02-22 | Benzon Pharma A/S | Oral composition containing particles comprising an active substance |
| US4950689A (en) | 1987-03-31 | 1990-08-21 | Yang Robert K | Pectin delivery system |
| US5215752A (en) | 1988-03-17 | 1993-06-01 | Vectorpharma International S.P.A. | Pharmaceutical tablets and capsule granulates of scleroglucan and active substance |
| US5273823A (en) | 1988-10-11 | 1993-12-28 | The Dow Chemical Company | Shaped articles containing copolymers of polybenzazoles |
| US4883660A (en) | 1988-10-17 | 1989-11-28 | Thames Pharmacal Co., Inc. | Gel bases for pharmaceutical compositions |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5102664A (en) | 1989-07-19 | 1992-04-07 | Day Charles E | Good-tasting gritty drug formulations |
| US5558880A (en) | 1989-12-22 | 1996-09-24 | Janssen Pharmaceutica Inc. | Pharmaceutical and other dosage forms |
| SE9003904D0 (en) | 1990-12-07 | 1990-12-07 | Astra Ab | METHOD FOR THE MANUFACTURE OF A PHARMACEUTICAL DOSAGE FORM |
| US5464632C1 (en) | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
| WO1993004670A1 (en) | 1991-08-30 | 1993-03-18 | Showa Yakuhin Kako Co., Ltd. | Dry gel composition |
| US5215758A (en) | 1991-09-11 | 1993-06-01 | Euroceltique, S.A. | Controlled release matrix suppository for pharmaceuticals |
| US5192802A (en) | 1991-09-25 | 1993-03-09 | Mcneil-Ppc, Inc. | Bioadhesive pharmaceutical carrier |
| US5318780A (en) | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
| US5545423A (en) | 1991-11-25 | 1996-08-13 | Vivorx, Inc. | Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials |
| US5368862A (en) | 1991-12-18 | 1994-11-29 | Merck & Co., Inc. | Sustained release tablets containing alginate |
| DE627218T1 (en) * | 1992-02-18 | 1995-08-24 | Nippon Shinyaku Co Ltd | QUICK-RELEASE TABLET. |
| US5422122A (en) | 1992-08-04 | 1995-06-06 | Eurand America, Incorporated | Controlled release potassium chloride tablet |
| IL104283A (en) | 1992-12-30 | 1996-12-05 | Agis Ind 1983 Ltd | Non-emulsion antiviral topical pharmaceutical composition comprising acyclovir an aqueous gel agent and an alkali oleate |
| US5562909A (en) | 1993-07-12 | 1996-10-08 | Massachusetts Institute Of Technology | Phosphazene polyelectrolytes as immunoadjuvants |
| US5595761A (en) | 1994-01-27 | 1997-01-21 | The Board Of Regents Of The University Of Oklahoma | Particulate support matrix for making a rapidly dissolving tablet |
| US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| FR2732217B1 (en) * | 1995-03-29 | 1997-06-06 | Hesnard Xavier | SOLID ADMINISTRATION FORM FOR ORAL USE |
| JP2919771B2 (en) * | 1995-04-17 | 1999-07-19 | 佐藤製薬株式会社 | Method for producing fast-dissolving tablet and fast-dissolving tablet produced by the method |
| US20010014340A1 (en) * | 1996-06-14 | 2001-08-16 | Motohiro Ohta | Intrabuccally rapidly disintegrating tablet |
| US6287596B1 (en) * | 1996-07-12 | 2001-09-11 | Daiichi Pharmaceutical Co., Ltd. | Quickly disintegratable compression-molded materials and process for producing the same |
| FR2753097A1 (en) * | 1996-09-11 | 1998-03-13 | Barrau Francois | Solid dosage form giving controlled viscosity solution or dispersion |
| KR100353304B1 (en) * | 1996-10-01 | 2002-09-30 | 에스알아이 인터내셔널 | Taste-masked microcapsule compositions and methods of manufacture |
| JPH10182436A (en) * | 1996-10-31 | 1998-07-07 | Takeda Chem Ind Ltd | Solid medicinal preparation |
| JPH10167958A (en) * | 1996-12-09 | 1998-06-23 | Sankyo Co Ltd | Loxoprofen sodium-containing oral cavity promptly soluble preparation and its production |
| US5728401A (en) * | 1997-04-16 | 1998-03-17 | Ranbaxy Laboratories, Ltd. | Effervescent ranitidine formulations |
-
1999
- 1999-08-11 US US09/372,738 patent/US6368625B1/en not_active Expired - Fee Related
- 1999-08-12 ES ES99941105T patent/ES2265188T3/en not_active Expired - Lifetime
- 1999-08-12 DE DE69931498T patent/DE69931498T2/en not_active Expired - Lifetime
- 1999-08-12 JP JP2000564593A patent/JP2002522471A/en active Pending
- 1999-08-12 AU AU54823/99A patent/AU742049B2/en not_active Ceased
- 1999-08-12 WO PCT/US1999/018400 patent/WO2000009090A1/en active IP Right Grant
- 1999-08-12 EP EP99941105A patent/EP1104288B1/en not_active Expired - Lifetime
- 1999-08-12 CA CA002339992A patent/CA2339992C/en not_active Expired - Fee Related
- 1999-08-12 AT AT99941105T patent/ATE326951T1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1104288A4 (en) | 2003-04-16 |
| ES2265188T3 (en) | 2007-02-01 |
| US6368625B1 (en) | 2002-04-09 |
| WO2000009090A1 (en) | 2000-02-24 |
| JP2002522471A (en) | 2002-07-23 |
| ATE326951T1 (en) | 2006-06-15 |
| DE69931498T2 (en) | 2007-03-01 |
| CA2339992A1 (en) | 2000-02-24 |
| AU742049B2 (en) | 2001-12-13 |
| DE69931498D1 (en) | 2006-06-29 |
| EP1104288B1 (en) | 2006-05-24 |
| EP1104288A1 (en) | 2001-06-06 |
| AU5482399A (en) | 2000-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2339992C (en) | Orally disintegrable tablet forming a viscous slurry | |
| JP2002522471A5 (en) | ||
| AU726336B2 (en) | Rapidly dissolving robust dosage form | |
| CA2335566C (en) | Effervescent drug delivery system for oral administration | |
| US5178878A (en) | Effervescent dosage form with microparticles | |
| EP1274398B1 (en) | Methods for thepreparation of effervescent granules | |
| US6365182B1 (en) | Organoleptically pleasant in-mouth rapidly disintegrable potassium chloride tablet | |
| ES2462536T3 (en) | Multi-layer orodispersible tablet | |
| US6740341B1 (en) | Taste masking rapid release coating system | |
| WO2003072084A1 (en) | Fast disintegrating tablets | |
| US6080427A (en) | Cefadroxil monohydrate tablet formulation | |
| EP1688131A1 (en) | Orally disintegratable tablet forming a viscous slurry | |
| AU2005202472A1 (en) | Effervescent drug delivery system for oral administration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |